These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Remyelinating strategies for the treatment of multiple sclerosis. Stangel M; Hartung HP Prog Neurobiol; 2002 Dec; 68(5):361-76. PubMed ID: 12531235 [TBL] [Abstract][Full Text] [Related]
3. Promoting repair in multiple sclerosis: problems and prospects. Lubetzki C; Williams A; Stankoff B Curr Opin Neurol; 2005 Jun; 18(3):237-44. PubMed ID: 15891406 [TBL] [Abstract][Full Text] [Related]
4. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. Keirstead HS; Blakemore WF Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029 [TBL] [Abstract][Full Text] [Related]
5. Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches. Olsen JA; Akirav EM J Neurosci Res; 2015 May; 93(5):687-96. PubMed ID: 25287108 [TBL] [Abstract][Full Text] [Related]
6. Remyelinating Pharmacotherapies in Multiple Sclerosis. Bove RM; Green AJ Neurotherapeutics; 2017 Oct; 14(4):894-904. PubMed ID: 28948533 [TBL] [Abstract][Full Text] [Related]
7. Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis. Motavaf M; Sadeghizadeh M; Javan M Cell Mol Neurobiol; 2017 Nov; 37(8):1335-1348. PubMed ID: 28224237 [TBL] [Abstract][Full Text] [Related]
8. The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges. Murphy RP; Murphy KJ; Pickering M Bioengineered; 2013; 4(3):140-6. PubMed ID: 23147071 [TBL] [Abstract][Full Text] [Related]
9. Promoting remyelination in multiple sclerosis: current drugs and future prospects. Kremer D; Küry P; Dutta R Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245 [TBL] [Abstract][Full Text] [Related]
17. Promoting remyelination in multiple sclerosis. Cunniffe N; Coles A J Neurol; 2021 Jan; 268(1):30-44. PubMed ID: 31190170 [TBL] [Abstract][Full Text] [Related]
18. Current status of myelin replacement therapies in multiple sclerosis. Huang JK; Franklin RJ Prog Brain Res; 2012; 201():219-31. PubMed ID: 23186717 [TBL] [Abstract][Full Text] [Related]
19. Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis. Gingele S; Stangel M Expert Opin Investig Drugs; 2020 Jun; 29(6):583-594. PubMed ID: 32348161 [TBL] [Abstract][Full Text] [Related]